Physician profile
Nancy E Jolly
NPI 1962905950
$1,522.45
in general payments reported to CMS, 2019-2025
15 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $568 · 2024: $456 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $299.82 | 2022-2024 | |
| Axsome Therapeutics, INC. | $231.38 | 2022-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $217.76 | 2022-2025 | Farxiga, Breztri |
| Amgen INC. | $195.49 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.75 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $138.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $69.82 | 2023-2024 | |
| Lilly USA, LLC | $69.60 | 2022-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $37.47 | 2023 | Trintellix |
| Globus Medical, INC. | $31.56 | 2025 | Senza |
| Idorsia Pharmaceuticals US INC | $17.31 | 2025 | Quviviq |
| Inspire Medical Systems, INC. | $17.22 | 2024 | Inspire |
| Pfizer INC. | $16.12 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.68 | 2023 | |
| Glaxosmithkline, LLC. | $15.54 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Jolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.